Funding influences exposure and review of cancer research

Funding influences exposure and review of cancer research
Abstracts submitted to the American Society of Clinical Oncology annual meeting by researchers who have financial relationships with commercial interests are more prominently placed and more favorably scored by peers, according to research published online June 17 in the Journal of Clinical Oncology.

(HealthDay)—Abstracts submitted to the American Society of Clinical Oncology (ASCO) annual meeting by researchers who have financial relationships with commercial interests are more prominently placed and more favorably scored by peers, according to research published online June 17 in the Journal of Clinical Oncology.

Beverly Moy, M.D., M.P.H., of the Massachusetts General Hospital Cancer Center in Boston, and colleagues analyzed 20,718 abstracts presented at ASCO meetings in 2006 and 2008 to 2011. The association of financial conflicts of interest (FCOIs) with meeting placement and peer review score was examined. On a scale of 1 to 5, lower peer-reviewed scores indicated greater scientific merit.

The researchers found that 36 percent of the abstracts had at least one author who reported an FCOI. A significant increase in the proportion of abstracts with any FCOI was observed for 2011 (38 percent) compared with 2006 (33 percent). Compared with general posters, abstracts with FCOIs were significantly more likely to receive placement (in descending order of meeting prominence) in plenary session (odds ratio [OR], 7.3), clinical science symposium (OR, 2.2), oral presentation (OR, 1.9), and poster discussion (OR, 1.7). For all abstracts except publish-only, those with FCOIs had a significantly more favorable mean peer-reviewed score (2.62) compared with those without FCOIs (2.73).

"Real and perceived financial conflicts of interest and risks of bias in the conduct and reporting of research represent important issues that necessitate strategies to safeguard the public," writes the author of an accompanying editorial.

Several study authors and the editorial author disclosed to the biomedical and/or .

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

More cutting-edge cancer research supported by industry

May 17, 2012

Nearly half of the research presented at ASCO's annual meeting last year came from researchers with ties to companies, and the amount appears to be increasing every year, according to new findings from Fox Chase Cancer Center. ...

ASCO: Cancer patients want to talk about costs with docs

May 31, 2013

(HealthDay)—Although financial distress is common, even in insured patients, discussion of costs of cancer care with doctors rarely happens, according to research to be presented at the annual meeting of ...

Recommended for you

Pepper and halt: Spicy chemical may inhibit gut tumors

12 hours ago

Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin – the active ingredient in chili peppers – produces chronic activation of a receptor on cells lining ...

Expressive writing may help breast cancer survivors

13 hours ago

Writing down fears, emotions and the benefits of a cancer diagnosis may improve health outcomes for Asian-American breast cancer survivors, according to a study conducted by a researcher at the University of Houston (UH).

Taking the guesswork out of cancer therapy

19 hours ago

Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular test ...

Brain tumour cells found circulating in blood

20 hours ago

(Medical Xpress)—German scientists have discovered rogue brain tumour cells in patient blood samples, challenging the idea that this type of cancer doesn't generally spread beyond the brain.

International charge on new radiation treatment for cancer

21 hours ago

(Medical Xpress)—Imagine a targeted radiation therapy for cancer that could pinpoint and blast away tumors more effectively than traditional methods, with fewer side effects and less damage to surrounding tissues and organs.

User comments